Previous 10 | Next 10 |
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its fourth quarter and full year 2019 financial results after the market closes on Wednesday, March 25, 2020. In conjunction with the release, the Company will host a conference call and...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Immuno-Oncology 360˚ conference in New York, February 26-28. The presentation , titled “Comprehensive Immunogenomics to Enable Composite Biomarkers fo...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at the Biomarkers Series UK 2020 conference in Manchester, UK, February 19-20. The presentation , titled “Maximizing Immunotherapy Biomarker Discovery with an A...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate at the upcoming Cowen 40 th Annual Health Care Conference. John West, Chief Executive Officer, will be presenting on Wednesday, March 4, 2020 at 8:40 a.m. E...
Advaxis (NASDAQ: ADXS ) and Personalis (NASDAQ: PSNL ) have collaborated to leverage Personalis’ ImmunoID NeXT Platform in Advaxis’ ongoing Phase 1/2 ADXS-503 (HOT Lung) program evaluating ADXS-503 alone and in combination with pembrolizumab in patients with non-small cell lu...
PRINCETON, N.J. and MENLO PARK, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced genomics for ca...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Precision Medicine World Conference (PMWC) 2020 in Santa Clara, CA January 22-24. The presentation titled “Enabling Advanced Composite Biomarkers for ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential therapies and clinical trial options for cancer patients. The Personalis NeXT Dx™ Test is one of the first cancer dia...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the ESMO Immuno-Oncology Congress 2019 in Geneva, Switzerland, December 11-14, including a poster presentation on December 12 th . The poster presentation , tit...
Are small-cap stocks poised for a breakout? That's what some analysts and hedge fund managers are arguing. The idea is that passive investing, or tossing a bunch of money into an index fund and forgetting about it because you have better stuff to do, is driving a wedge between small compa...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate virtually at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 13, 2024. About Personalis, Inc. At Personalis, ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...